China approves Eli Lilly's weight loss pill orforglipron

NBD

China has approved Eli Lilly's weight loss pill orforglipron, making it the country's first approved oral GLP-1 obesity treatment.

The pill will compete for market share in China with the once-weekly GLP-1 weight-loss injections from Novo Nordisk, Pfizer, and local firms like Innovent Biologics.

Most Popular

1 Samples Sold Out, Orders Booming: How Chinese Innovation Is Winning Over Global Buyers at the Canton Fair
2 Exclusive interview at CIIE with Dolce & Gabbana Beauty CEO
3 China’s "Duanju" Goes Global: Micro-Short Dramas Take World Stage
4 China approves Eli Lilly's weight loss pill orforglipron
5 Apple Intelligence Approved in China, Beta Launching Late October; iPhone Duo will be manufactured entirely in Chinese factories
6 The 7th BRITACOF Concludes with Six Key Outcomes
7 Developed Market Debt to Hit Record $75.8 trillion! Fitch Warns High Yields Squeeze Advanced Economies and Three Indicators Could Hit Sovereign Credit Ratings